Ipsen SA
SWB:I7G
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Ipsen SA
SWB:I7G
|
FR |
|
R
|
Roche Holding AG
DUS:RHO5
|
CH |
|
Ardelyx Inc
NASDAQ:ARDX
|
US |
|
Marker Therapeutics Inc
NASDAQ:MRKR
|
US |
|
I
|
Informa PLC
OTC:IFPJF
|
UK |
|
Eagle Materials Inc
NYSE:EXP
|
US |
|
E
|
Essent Group Ltd
XBER:EG0
|
BM |
|
Guangdong Investment Ltd
HKEX:270
|
HK |
|
O
|
ON Semiconductor Corp
F:XS4
|
US |
|
F
|
FibroGen Inc
BMV:FGEN
|
US |
|
Isuzu Motors Ltd
F:ISUA
|
JP |
|
T
|
Tetra Tech Inc
SWB:TT6
|
US |
|
Arca Continental SAB de CV
F:AJZ
|
MX |
Ipsen SA
Ipsen is a French specialty pharmaceutical company that develops and sells prescription medicines for serious diseases, especially in oncology, rare diseases, and certain neurological conditions. Its business is built around branded drugs that doctors prescribe in hospitals and clinics, rather than over-the-counter products. The company makes money by selling these medicines to hospitals, healthcare providers, and pharmaceutical distributors around the world. It also relies on partnerships and licensing deals in some areas of research and commercialization, which helps it bring products to market without doing every step alone. What makes Ipsen different is its focus on a narrower set of hard-to-treat diseases where patients need specialized care and long-term treatment. That gives it a role as a focused drug maker: it does not try to be a broad consumer health company, but instead sells targeted therapies in niche medical markets where scientific expertise and physician trust matter most.
Ipsen is a French specialty pharmaceutical company that develops and sells prescription medicines for serious diseases, especially in oncology, rare diseases, and certain neurological conditions. Its business is built around branded drugs that doctors prescribe in hospitals and clinics, rather than over-the-counter products.
The company makes money by selling these medicines to hospitals, healthcare providers, and pharmaceutical distributors around the world. It also relies on partnerships and licensing deals in some areas of research and commercialization, which helps it bring products to market without doing every step alone.
What makes Ipsen different is its focus on a narrower set of hard-to-treat diseases where patients need specialized care and long-term treatment. That gives it a role as a focused drug maker: it does not try to be a broad consumer health company, but instead sells targeted therapies in niche medical markets where scientific expertise and physician trust matter most.
Strong Q1: Ipsen said total sales rose 22.6% in Q1, with growth coming from all three therapeutic areas and especially the portfolio outside Somatuline, which grew 27.5%.
Guidance held: Management confirmed 2026 guidance for sales growth greater than 13% at constant exchange rates and a core operating margin greater than 35% of sales.
Somatuline boost: Somatuline benefited from generic stockouts and recaptured share and pricing, but management stayed cautious because generic competition could return in H2 2026, with Amneal saying it may launch in Q3.
Rare disease momentum: Iqirvo and Bylvay both showed strong momentum, helped by U.S. growth, broader European rollout, and, for Bylvay, the new dedicated field force.
Pipeline catalyst year: Ipsen highlighted three pivotal Phase III readouts expected in H2 2026 and said it is starting three late-stage trials, including corabotase in glabellar lines and Iqirvo in PSC.
Corabotase optionality: Management said it has full rights to corabotase and is evaluating all commercialization scenarios, while stressing strong interest in both aesthetics and therapeutics.
